ASH 2023 | Predictors of achieving undetectable BCR::ABL1 in patients with ALL
Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a retrospective study investigating the predictors of achieving an undetectable BCR::ABL1 transcript in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The barriers to this were identified as a high white blood cell (WBC) count, the presence of a p210 transcript, additional cytogenic abnormalities, and the use of less intensive chemotherapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
